$42,223.99 speaking Payment -- AbbVie Inc to Dr. Rachel Parker

Payment Details

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

This payment of $42,223.99 from AbbVie Inc. to Dr. Rachel Parker, a rheumatologist in Jersey City, NJ, on July 6, 2025, was for her role as a speaker or faculty member. This type of payment, often referred to as 'honoraria' for educational activities, is common in the pharmaceutical industry. Rheumatologists, who specialize in conditions like arthritis and autoimmune diseases, often manage complex treatment plans involving expensive medications. Therefore, pharmaceutical companies frequently engage them to educate other healthcare professionals about new therapies or disease management strategies. The amount itself is substantial, suggesting Dr. Parker may have delivered multiple presentations or a significant educational event. While this payment is for educational services, it's important for patients to be aware of potential conflicts of interest. When a doctor receives significant compensation from a drug manufacturer, it could theoretically influence their prescribing habits, even unconsciously. However, it's crucial to remember that such payments are legal and regulated under the Sunshine Act, and do not automatically mean a doctor's judgment is compromised. Many physicians engage in these activities to share valuable expertise. Compared to industry averages, this payment is on the higher end for speaking engagements, but not entirely out of the realm of possibility for a highly sought-after expert in a specialized field like rheumatology. Patients should view this information as a piece of the puzzle in understanding their doctor's professional relationships, encouraging open communication rather than immediate suspicion. The key is transparency and understanding the context of these financial ties.

Patient Guidance: What This Payment Means for You

It's understandable to feel curious or concerned when you see payments between pharmaceutical companies and your doctor. The Sunshine Act aims to make these relationships transparent. This payment to Dr. Parker was for her expertise as a speaker, likely educating others on rheumatology topics. While the amount is significant, it doesn't automatically mean your care is compromised. At your next appointment, you can ask your doctor directly: 'I saw on the Open Payments database that you received a payment from AbbVie for speaking. Can you tell me more about that engagement?' This opens a dialogue. Remember, many doctors participate in these educational roles to share knowledge. However, it's always wise to be an informed patient. If you have concerns about your treatment plan or prescribed medications, discuss them openly. Ask why a particular medication is recommended and if there are alternatives. Payments for speaking or consulting are generally considered routine for specialists, but if a doctor consistently receives large sums from a single company, or if their prescribing patterns seem unusual, it might warrant further consideration. The goal is to ensure your treatment is based on your individual needs and the best medical evidence.

Payment Context: Is This Amount Normal?

For rheumatologists, payments for speaking engagements can vary widely but often fall into the thousands of dollars for a single event. An amount like $42,223.99 suggests a significant educational role, possibly involving multiple engagements or a major conference. While not every rheumatologist receives such payments, a notable percentage do engage with pharmaceutical companies in various capacities, including speaking. This payment is on the higher side for a single speaking engagement but can be considered within the range for highly regarded experts in the field.

Regulatory Context: Sunshine Act Requirements

The Sunshine Act, part of the Affordable Care Act, requires pharmaceutical companies and medical device manufacturers to report payments and other transfers of value made to physicians and teaching hospitals. Payments exceeding a de minimis threshold (which can vary but is generally low for direct payments) must be reported. This $42,223.99 payment for speaking clearly exceeds reporting thresholds. While this type of payment is subject to reporting, it is not inherently scrutinized more than other forms of compensation unless specific concerns about kickbacks or illegal inducements arise.

Related Topics

This payment is related to the following healthcare transparency topics:

• pharma-payments
• rheumatology
• speaker-honoraria
• sunshine-act
• physician-compensation
• abbvie
• conflict-of-interest

Understanding speaking Payments

Speaking and education payments compensate physicians for presenting at conferences, continuing medical education (CME) events, and promotional speaking engagements. These payments often cover honoraria, preparation time, and travel expenses. Speaking fees are among the highest-value payment categories and have attracted significant attention from researchers studying potential conflicts of interest.

Frequently Asked Questions About This Payment

Does my doctor take pharma money?

You can find out by searching the Centers for Medicare & Medicaid Services (CMS) Open Payments database online. This database lists payments made by pharmaceutical and medical device companies to physicians and teaching hospitals. If your doctor's name appears, it means they have received some form of payment or transfer of value. It's important to remember that not all payments are problematic; many are for legitimate educational activities, research, or consulting. However, transparency allows you to understand potential influences on your care and have informed conversations with your doctor.

Should I worry about this payment?

This specific payment of over $42,000 to Dr. Parker for speaking is substantial, indicating a significant educational role. While it's a large sum, it doesn't automatically mean your care is compromised. Many physicians are compensated for sharing their expertise, which can be valuable for medical education. Consider it a data point. If you have concerns about your treatment, discuss them directly with Dr. Parker. Ask about the rationale behind your treatment plan and if there are alternatives. The key is open communication and ensuring your treatment aligns with your health needs.

What types of pharma payments are most concerning?

Payments that raise the most concern are often those that could directly influence prescribing without clear educational or research value. This includes large, unrestricted 'educational grants' to physicians or organizations that don't clearly define the educational activity, lavish meals or travel, or payments for consulting that don't seem to align with actual work performed. Payments for speaking, like the one to Dr. Parker, are common but the size and frequency can be factors. Payments tied directly to the volume of prescriptions or sales of a specific drug are illegal kickbacks and highly concerning.

How do I talk to my doctor about pharma relationships?

Approach the conversation with curiosity and a desire for understanding, not accusation. You could say, 'I was looking at the Open Payments database and saw you received a payment from [Company Name] for [reason, e.g., speaking]. Could you tell me more about that?' Or, 'I'm interested in understanding how you stay up-to-date with new treatments. Do you work with pharmaceutical companies in any educational capacity?' Listen to their explanation. You can also ask, 'When considering my treatment options, how do you weigh the different medications available, especially those from companies you may have relationships with?'

Is it legal for doctors to accept pharma payments?

Yes, it is legal for doctors to accept payments from pharmaceutical and medical device companies, provided these payments comply with federal laws and regulations. The Sunshine Act mandates reporting of most payments to ensure transparency. However, laws like the Anti-Kickback Statute prohibit payments made with the intent to induce the referral of federal healthcare program business. So, while accepting payment is legal, the *purpose* of the payment matters. Companies cannot legally pay doctors to prescribe their drugs; payments must be for legitimate services like speaking, consulting, research, or medical education.

Does pharma money affect what my doctor prescribes?

Research suggests that financial relationships between doctors and pharmaceutical companies can, on average, influence prescribing patterns. Doctors who receive payments may be more likely to prescribe the drugs made by the companies they have relationships with. However, this influence is complex and doesn't mean every doctor's judgment is compromised. Many factors influence prescribing decisions, including patient needs, clinical guidelines, and personal experience. The Sunshine Act aims to provide transparency so patients can have informed discussions about these potential influences.

How does this compare to other doctors in this specialty?

In rheumatology, it's common for specialists to engage with pharmaceutical companies, as many treatments for rheumatic diseases are developed and marketed by these companies. Payments for speaking, consulting, and research are not unusual. While the exact average varies, a payment of over $42,000 for speaking is on the higher end, suggesting Dr. Parker is likely a recognized expert or educator in her field. Many rheumatologists receive some form of payment, but the amount and frequency can differ significantly. This payment is more substantial than what many physicians receive annually, but not unprecedented for a specialist involved in significant educational activities.

Related Reports

• View Dr. Rachel Parker's full payment report
• AbbVie Inc full spending report
• Browse all Rheumatology payments
• Browse all payments in New Jersey
• Search for other payments